文献速递临床试验与 GCP基础与转化研究

柚皮素补充对超重/肥胖非酒精性脂肪性肝病患者的影响:随机双盲临床试验研究方案

Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial.
PubMed 文献 · Trials · 2021-11-13

该研究为随机双盲安慰剂对照临床试验方案,计划纳入44例超重/肥胖的非酒精性脂肪性肝病(NAFLD)患者,随机接受柚皮素胶囊(每粒100 mg)或安慰剂,每日两次,持续4周。主要结局为循环脂联素水平变化,次要结局包括神经调节蛋白-4(NRG-4)、肝功能指标、代谢参数等。作者假设柚皮素可能通过调节能量平衡、糖脂代谢、氧化应激和炎症对NAFLD产生治疗作用。

要点

  • 纳入44例超重/肥胖NAFLD患者,随机接受柚皮素100 mg胶囊或安慰剂,每日两次,共4周。
  • 主要结局为血浆脂联素水平变化,次要结局包括NRG-4、肝功能、代谢指标及人体测量指标。
  • 作者假设柚皮素可能通过调节能量平衡、糖脂代谢、氧化应激和炎症对NAFLD产生治疗作用。

核心结论

  • 作者假设柚皮素给药可能通过不同机制调节能量平衡、糖脂代谢、氧化应激和炎症,从而对NAFLD有治疗作用。
  • 当前试验将展示柚皮素对NAFLD状态的影响,无论阴性或阳性结果。

研究设计与样本

  • 双盲、随机、安慰剂对照临床试验。
  • 计划选取44例符合条件的超重/肥胖NAFLD患者,随机分配接受柚皮素胶囊或相同安慰剂(每粒含100 mg柚皮素或纤维素),每日两次,持续4周。
  • 采用肝脏超声诊断NAFLD,要求参与者保持日常饮食和体力活动。
  • 柚皮素补充的安全性由研究药剂师确认。
  • 统计分析使用SPSS软件(版本25),P值小于0.05视为有统计学意义。

关键数值与推荐

  • 主要结局为循环脂联素水平的变化。
  • 次要结局包括NRG-4水平、肝功能指标、代谢参数、体重、体质指数(BMI)、腰围、血压和血液学参数的变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is one of the main causes of chronic liver disease worldwide. Flavonoids, a group of natural compounds, have garnered a great deal of attention in the management of NAFLD because of their profitable effects on glucose and lipid metabolism, inflammation, and oxidative stress which are the pivotal pathophysiological pathways in NAFLD. Naringenin is a citrus-derived flavonoid with a broad spectrum of potential biological effects including anti-inflammatory and antioxidant properties, which may exert protective effects against NAFLD. The present clinical trial aims to examine the efficacy of naringenin supplementation on plasma adiponectin and neurogulin-4 (NRG-4) concentrations, metabolic parameters, and liver function indices in overweight/obese patients with NAFLD. METHODS AND ANALYSIS: This is a double-blind, randomized, placebo-controlled clinical study that will investigate the impacts of naringenin supplementation in overweight/obese patients with NAFLD. Liver ultrasonography will be applied to diagnose NAFLD. Forty-four eligible overweight/obese subjects with NAFLD will be selected and randomly assigned to receive naringenin capsules or identical placebo (each capsule contains 100 mg of naringenin or cellulose), twice daily for 4 weeks. Participants will be asked to remain on their usual diet and physical activity. Safety of naringenin supplementation was confirmed by the study pharmacist. The primary outcome of this study is changes in adiponectin circulating levels. The secondary outcomes include changes in NRG-4 levels, liver function indices, metabolic parameters, body weight, body mass index (BMI), waist circumference (WC), blood pressure, and hematological parameters. Statistical analysis will be conducted using the SPSS software (version 25), and P value less than 0.05 will be regarded as statistically significant. DISCUSSION: We hypothesize that naringenin administration may be useful for treating NAFLD by modulating energy balance, glucose and lipid metabolism, oxidative stress, and inflammation through different mechanisms. The current trial will exhibit the effects of naringenin, whether negative or positive, on NAFLD status. ETHICAL ASPECTS: The current trial received approval from the Medical Ethics Committee of Tehran University of Medical Sciences, Tehran, Iran (IR.TUMS.MEDICNE.REC.1399.439). TRIAL REGISTRATION: Iranian Registry of Clinical Trials IRCT201311250155336N12 . Registered on 6 June 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Naeini F, Namkhah Z, Tutunchi H, et al. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial. Trials. 2021. PMID: 34774104. doi:10.1186/s13063-021-05784-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。